For a computed tomography coronary angiography performed in the morning, should I hold apixaban (Eliquis) the night before a possible left heart catheterization if the CT coronary angiogram is positive?

Do Not Hold Eliquis the Night Before CT Coronary Angiography

You should continue Eliquis without interruption for the CT coronary angiography, as this is a purely diagnostic imaging study with no bleeding risk that does not require anticoagulation interruption.

Rationale for Continuing Anticoagulation

CT coronary angiography (CCTA) is a non-invasive imaging procedure that involves only intravenous contrast administration—there is no arterial puncture, no catheter manipulation, and essentially zero bleeding risk. This is fundamentally different from invasive left heart catheterization (LHC).

Key Distinction: Diagnostic Imaging vs. Invasive Procedure

• CCTA is purely diagnostic imaging: No vascular access, no procedural bleeding risk
• The "possible LHC" is speculative: You cannot justify stopping anticoagulation based on a hypothetical future procedure that may never occur
• If CCTA is negative: No intervention needed, and you would have unnecessarily interrupted anticoagulation and increased stroke risk
• If CCTA is positive: You have time to properly plan anticoagulation management before the scheduled LHC

Evidence-Based Anticoagulation Management

For the Actual LHC (If Needed After Positive CCTA)

The most recent and comprehensive perioperative guidelines 1 provide clear direction for apixaban management:

For diagnostic cardiac catheterization with possible PCI:

• Low-to-moderate bleeding risk procedures: Hold apixaban for 1 day (skip 2 doses) before the procedure
• High bleeding risk procedures: Hold apixaban for 2 days (skip 4 doses) before the procedure

This is corroborated by the 2022 CHEST guidelines 2, which specify identical timing based on normal renal function.

Radial Access Considerations

Multiple studies demonstrate that uninterrupted anticoagulation is safe for radial access procedures 3, 4. If LHC becomes necessary:

• Radial approach with continued anticoagulation is a viable option
• Significantly lower bleeding risk than femoral access
• Consider this approach if urgent catheterization is needed

Practical Management Algorithm

Current Situation (Pre-CCTA):

1. Continue Eliquis as prescribed through the CCTA
2. Perform CCTA in the morning as scheduled
3. No bridging, no interruption needed

If CCTA Shows Significant Disease Requiring LHC:

1. Schedule elective LHC (not same-day emergency)
2. Hold Eliquis starting 24 hours before LHC (for standard bleeding risk diagnostic catheterization with possible PCI)
3. Last dose of Eliquis: Morning dose the day before the procedure (if LHC scheduled for morning)
4. Resume Eliquis: After hemostasis is achieved post-procedure, typically same day or next morning 5

Timing Example:

• Monday AM: CCTA performed (on Eliquis)
• Tuesday: Schedule LHC for Thursday AM
• Wednesday AM: Last Eliquis dose
• Wednesday PM: Hold Eliquis
• Thursday AM: LHC performed (24 hours off Eliquis)
• Thursday PM: Resume Eliquis after hemostasis confirmed

Critical Pitfalls to Avoid

Do not hold anticoagulation "just in case": This approach:

• Increases stroke/thrombosis risk unnecessarily
• Is not supported by any guideline
• Assumes a positive CCTA result that may not occur
• Violates the principle of risk-benefit assessment

The FDA label for Eliquis 5 specifies:

• Discontinue at least 48 hours prior to elective surgery with moderate-to-high bleeding risk
• Discontinue at least 24 hours prior to procedures with low bleeding risk
• Diagnostic cardiac catheterization falls into the low-to-moderate category

Special Considerations

Renal Function

If creatinine clearance is <30 mL/min, extend the interruption period:

• Hold for 2 days even for low-moderate bleeding risk procedures 1, 2
• Apixaban has 27% renal clearance and prolonged half-life in renal impairment 6

Stroke Risk Assessment

For patients with high stroke risk (CHA₂DS₂-VASc ≥4, recent stroke, mechanical valve):

• Even more critical to avoid unnecessary interruption
• Consider radial access with uninterrupted anticoagulation if urgent catheterization needed 7

No Bridging Required

Do not bridge with heparin or LMWH during the brief interruption period for elective LHC 1, 2. Bridging:

• Increases bleeding risk
• Provides no benefit for short interruptions (24-48 hours)
• Has similar pharmacokinetics to DOACs, making it redundant

Bottom Line

Continue Eliquis through the CCTA. If the scan shows disease requiring intervention, you will have adequate time to hold Eliquis for 24 hours before a properly scheduled LHC. Stopping anticoagulation preemptively for a diagnostic imaging study with zero bleeding risk is not evidence-based and exposes your patient to unnecessary thrombotic risk.